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Introduction
Decision-making process about the development 
of new products is fundamental for the growth 
and prosperity of any company, particularly in 
the fast changing medical device market (Ivlev 
et al., 2015). Companies must innovate to be 
successful but this invariably carries some 
risk and uncertainty. In recent years, the issue 
of evaluation of investment effectiveness into 
medical devices has been intensively solved, 
both at national and international level (Heintz et 
al., 2016) due to the growing market with medical 
devices (Craig et al., 2014). Johal and Williams 
(2007) present three groups of decision making 
tools/techniques, which can help policy makers 
in the improvement of their early decisions on 
the development of a new product. These three 
groups of techniques consist of 1. strategic and 
fi nancial valuation of projects (e.g., NPV, IRR, 
DCF), 2. weighting and scoring of products and 
product criteria (e.g., analytic hierarchy process 
(AHP) and conjoint analysis), 3. human decision-
making (fuzzy logic, actuarial models, neural 
networks, technology road mapping and expert 
systems).
Currently, the most common and well-
established method for the assessment 
of medical devices is health technology 
assessment (HTA). As Ciani et al. (2015) 
explain, HTA aims to provide policy makers with 
information on the clinical and economic value of 
health technologies (including pharmaceuticals, 
medical devices, clinical procedures, and 
organizational systems used in health care) 
in order to support their reimbursement or 
coverage decisions (Ivlev et al., 2014; Rosina 
et al., 2014; Rogalewicz, 2016). In fact, HTA 
plays the key role in informing reimbursement 
and pricing decisions and providing clinical 
guidance on the use of medical technologies 
across the world (Stephens, Handke, & Dshi, 
2012; Rogalewicz, Bartak, & Kubatova, 2015).
One of the important methods of HTA is 
an economic evaluation which comprises 
a number of economic methods. The economic 
evaluation (EE) is a comparison of the costs 
and consequences of at least two choices 
(Drummond et al., 2005). With respect to 
new health technologies, EE compares the 
new health technology against the current 
standard-of-care treatment (Gavurova 
& Soltes, 2016; Gavurova & Vagasova, 2016). 
Sometimes, EE is called a cost-effectiveness 
analysis as it combines an analysis of costs and 
clinical effectiveness (EUPATI, 2017; Canadian 
Agency for Drugs and Technologies in Health, 
2006; Rotter, Foerster, & Bridges, 2012).
The EE processes are well-established 
in HTA of pharmaceuticals but not that much 
in the development of medical devices (Craig 
et al., 2014). The problem is that complete 
standardization of economic evaluations cannot 
be performed since the methods should be 
fl exible enough to be compatible with different 
problems in different contexts (Mathes et al., 
2013; Soltes & Gavurova, 2015). In addition, 
as Rotter, Foerster, and Bridges (2012) argue, 
several different approaches can be potentially 
applied in decision modelling. Drummond, Griffi n, 
and Tarricone (2009) in their study summarize the 
main reasons why assessments of devices differ 
from assessments of drugs, which are as follows:
 many devices are diagnostic; that is why 
the outcome cannot be separated from the 
treatment and, such devices have multiple 
applications;
 due to a short lifetime of devices, their 
frequent modifi cations, and the existence 
of “learning curves”, there is unlikely to be 
a substantial steady-state period, during 
which the device could be evaluated in an 
RCT;
 the effectiveness of a device depends 
both on the device itself and the way how 
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it is used (e.g., the skill and experience of 
a doctor);
 introduction of a new treatment comprising 
a device may have wider economic 
implications;
 equivalent clinical evidence may not 
be available for all products, making 
comparisons diffi cult;
 prices may change in the course of time 
since new products penetrate the market, or 
because of the ways, in which purchasing is 
held.
The purpose of this review focuses on 
the exploration of the economic methods, 
commonly used in the economic evaluation 
as part of health technology assessment for 
medical devices. On the basis of the selected 
original studies, the authors summarize the 
main economic methods used in the decision-
making processes about the development of 
new medical devices and discuss their benefi ts 
and limitations.
1. Methods
The methods included a method of literature 
search in the acknowledged databases for 
economic evaluations as suggested by Thielen 
et al. (2016). Search method followed the 
PRISMA guidelines for conducting systematic 
reviews (Moher et al., 2009). To ensure optimal 
coverage, additional articles were found within 
the reference section of retrieved articles and 
through citation snowballing by undertaking 
wider searches by author name for those 
appearing as key publishers in the area.
The databases thus were Web of Science, 
MEDLINE, and Embase. The authors searched 
relevant studies for the following key words: 
economic methods AND health technology 
assessment, economic methods AND HTA, 
economic evaluation AND health technology 
assessment, economic evaluation AND HTA, 
economic methods AND medical device AND 
health technology assessment.
The search period started in 2000 when 
the studies on the research topic started to 
appear and ends in December of 2016. Most 
of the articles were found in MEDLINE (2,648), 
followed by Embase (1,060), and Web of 
Science (986). In the last one, an increase in 
the number of articles on the research topic 
was the most obvious.
Articles that met the inclusion criteria 
of the quality of research papers were 
evaluated according to adequate description 
of the theoretical framework, background, and 
methodology (Mays & Pope, 2000).
For those papers that fulfi lled the criteria 
for quality, data was extracted according to the 
following content: date published, study funding 
source, possible confl icts of interest, study 
objectives, target population, application of tool, 
site/setting, study focus, HTA tool proposed 
or approach used in the paper, description 
of tool or approach, stand alone or support 
tool, aspects of clinical effectiveness, costs, 
and contextual issues, addressed by tool or 
approach, all stakeholders involved, literature 
search incorporated, results of implementation, 
and focus on medical technology/intervention.
Although the number of articles on the 
research topic is growing, most of the studies 
focused on the economic evaluations of 
pharmaceuticals and treatment. The inclusion 
criteria were as follows: the study was included if 
it were written in English, if it was original research 
study, not a review, if it covered the designated 
period, i.e., 2000-2016, and if it concerned the 
research topic, i.e., economic methods used 
in HTA for medical devices. In this review, the 
product is a medical device and it refers to a class 
II device (e.g., blood pressure monitors, contact 
lenses, pregnancy test kits, single-use surgical 
instruments, catheters), a class III device (e.g., 
ventilators, cardiac monitors, hip implants, knee 
implants, lasers, chlamydia test kits, glucose 
meters), or a class IV device (e.g., defi brillators, 
pacemakers, coronary stents, HIV test kits, 
neurosurgical shunts) that requires product 
licensing for general marketing purposes. The 
original research articles or clinical studies, 
however, were considered only back to the 
years of 2014-2016 since several review studies 
on this topic had been made before or even in 
this period, e.g., (Cooper et al., 2013; Craig et 
al., 2014; Markewicz, van Til, & Ijzerman, 2014; 
Mathes et al., 2013; Pham et al., 2014; Rotter, 
Foerster, & Bridges, 2012; Stephens, Handke, & 
Dshi, 2012).
Thus, after the identifi cation of the relevant 
studies on the basis of their key words and their 
titles, the duplicated studies were excluded. 
Afterwards, the abstracts were screened and, 
eventually, only 39 remained for the full-text 
analysis, out of which 11 studies were then used for 
a detailed analysis of the economic methods. The 
fi ndings from the selected studies are discussed 
and compared in the part on Discussion.
EM_1_2018.indd   117 21.3.2018   12:01:46
118 2018, XXI, 1
Ekonomika a management
2. Findings
The search retrieved 4,694 papers in total, out 
of which eleven fulfi lled the inclusion criteria 
(PRISMA fl owchart, Fig. 1). Data was extracted 
from the eleven papers published between 
2000 and 2016.
Altogether 11 studies were identifi ed 
according to the inclusion criteria described 
above. Nine studies were randomized 
controlled trials (Ashby et al., 2014; Downing 
et al., 2015; Harron et al., 2016; Lall et al., 
2015; Murray et al., 2014; Rosenthal et al., 
2015; Smulders et al., 2016; Walter et al., 
2015), usually comparing clinical benefi ts and 
cost-effectiveness of the traditional device 
with a new developed one, one study was 
a prospective study (Dozet et al., 2016), 
using a cost-minimization analysis for societal 
impact reasons, and one was a survey (Heintz 
et al., 2016), conducted among 33 European 
countries, which are involved in the European 
Network for Health Technology Assessment. 
The aim of this survey was to provide a general 
framework for economic evaluation at 
a European level. In the majority of the studies 
(9 studies) a cost-effectiveness was used. In 
some of these studies it was accompanied by 
a cost-utility analysis (3 studies), one study 
exclusively exploited the cost-utility analysis 
and one cost-minimization analysis. The studies 
are presented in alphabetical order of their fi rst 
author. Consult Tab. 1 below.
3. Discussion
As the fi ndings in Tab. 1 indicate, the most 
common economic method used in the economic 
evaluation of the medical device development 
is the cost-utility analysis (cf. Ashby et al., 
2014; Downing et al., 2015; Heintz et al., 
2016; Lall et al., 2015; Murray et al., 2014; 
Rosenthal et al., 2015; Smulders et al., 2016), 
followed by the cost-effectiveness analysis
Study Medical device Economic method(s) used
Ashby et al. (2014)
Randomized controlled trial 
(RCT)
Compression hosiery compared versus 
compression bandaging
Cost-utility analysis
Downing et al. (2015)
Cluster RCT
Non-pneumatic anti-shock garment fi rst aid 
device
Cost-utility analysis 
Dozet et al. (2016)
Prospective study
Mobile radiography technology Cost-minimization analysis
Featherstone et al. (2016)
RCT
Carotid artery stenting versus carotid 
endarterectomy 
Cost-effectiveness analysis
Harron et al. (2016)
RCT
Impregnated central venous catheters 
versus standard central venous catheters
Cost-effectiveness analysis
Heintz et al. (2016)
Survey study
Different types of devices Cost-utility analysis, 
cost-effectiveness analysis, 
cost-minimization analysis, 
cost-consequence analysis
Lall et al. (2015)
RCT
Conventional artifi cial ventilation versus 
high/frequency oscillatory ventilation
Cost-utility analysis 
Murray et al. (2014)
RCT
Knee prostheses Cost-utility analysis
Rosenthal et al. (2015)
RCT
Split-septum and single-use prefi lled fl ushing 
devices versus 3-way stopcock
Cost-utility analysis 
Smulders et al. (2016)
RCT
Simultaneous bilateral cochlear implantation 
versus unilateral cochlear implantation
Cost-utility analysis
Walter et al. (2015)
RCT
Metal stents versus plastic stents Cost-effectiveness analysis
Source: own
Tab. 1: An overview of the studies focusing on the economic assessment of medical devices
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(cf. Downing et al., 2015; Dozet et al., 2016; 
Heintz et al., 2016; Rosenthal et al., 2015), 
the cost-minimization analysis (cf. Dozet et 
al., 2016; Heintz et al., 2016), and the cost-
consequence analysis (cf. Heintz et al., 2016). 
These fi ndings are in compliance with other 
research studies on this topic such as Brockis 
et al. (2006) or Mathes et al. (2013).
The cost-utility analysis (CUA) is mostly 
preferred and widely accepted because it 
enables a comparison between different 
indications and types of health technology, 
especially in state-funded health care systems. 
Its outcomes are measured as health-related 
preferences, described as Quality Adjusted 
Life Years (QALYs) gained. CUA is used when 
interventions can infl uence the health related 
quality of life and the length of life (Canadian 
Agency for Drugs and Technologies in Health, 
2006). In addition, CUA aims at a higher 
level of standardization because the same 
denomination is used for all types of health 
technology and the methods to determine it 
can be better standardized (Mathes et al., 
2013). As the survey study (Heintz et al., 2016) 
reveals, most European countries use CUA 
as the main type of economic analysis. CUA 
is considered to be better at providing a more 
complete analysis of total benefi ts than the 
cost-benefi t analysis, which aims at estimating 
the strengths and weaknesses of alternatives 
(Gavurova & Vagasova, 2016). However, CUA 
has certain limitations. As Penner (2017) states, 
it relies on estimates of QALYs (for further 
discussion of QALY in HTA Rogalewicz and 
Bartak (2017)) which may not be relevant for 
application in the CUA. Furthermore, there may 
be confl icting ideas about how to approach the 
assessment of human life and disability (Soltes 
& Gavurova, 2015). Another problem seems to 
be the absence of incorporating the patient’s 
willingness to pay in decisions to fi nance new 
treatments (NICE, 2013).
The second mentioned and commonly used 
economic method is the cost-effectiveness 
analysis (CEA), which could be implemented 
as a secondary analysis when the use of an 
important patient outcome measure (other 
than a QALY gained) could be justifi ed if there 
is evidence of a meaningful difference in such 
an outcome compared with alternatives 8. 
As Weintraub and Cohen (2009) claim, CEA 
is an approach that can be used to extend 
the understanding of effi cacy data, which are 
frequently retrieved from RCTs. If it is relevantly 
applied, in some cases it may be more benefi cial 
than comparisons of cost alone, sometimes 
called cost-minimization studies, which implicitly 
suggest equivalence of effi cacy. There are also 
limitations of CEA in terms of methodological 
diffi culties such as measurement. CEA results 
can be only compared with the results of other 
technologies that are expressed in the same 
outcome measure. In addition, there might 
be ethical issues about the low acceptance of 
valuing health in monetary units in some societies 
(Mathes et al., 2013). Both CEA and CUA are 
expressed as an incremental cost-effectiveness 
ratio (ICER), i.e., the ratio of change in costs to 
the change in effects (What is the incremental 
cost-effectiveness ratio (ICER, 2017).
The third method implemented in the 
studies in Tab. 1 is the cost-minimization 
analysis (CMA). This method focuses on 
measuring and comparing the costs of different 
medical interventions. Thus, for example, 
the Scottish Medicines Consortium (SMC) 
recommend the use of CMA for therapeutically 
equivalent treatments established through 
non-inferiority studies; indirect comparisons 
showing statistically insignifi cant difference; 
or where cost-utility analysis shows extremely 
small quality-adjusted life year differences 
between treatments, however, the comparators 
must be appropriate and effectiveness must 
be comparable (Marshall et al., 2015). The 
principal limitations of this cost evaluation 
method are that it can only be used to compare 
treatments that provide the same benefi ts 
or effectiveness (identical outcomes, e.g., 
therapeutic effects); moreover, costs need to be 
determined accurately. In this way, a decision 
maker can choose the treatment with the lowest 
total cost. The assessment of costs is performed 
by identifying the study’s perspective, all the 
resources used, and quantifying them into 
physical units (Duemas, 2013).
The last method mentioned in Tab. 1 is 
the cost-consequence analysis (CCA), which 
provides disaggregated costs and a range of 
outcomes such as intervention costs, hospital 
costs, clinical benefi ts, and adverse effects 
(Drummond et al., 2005). It can be benefi cial 
for illustrating the impact of the intervention and 
it can be used as intermediate step for another 
type of evaluation. On the contrary, CCA is 
demanding for aggregating, weighing, and 
valuing the components on the user of the study 
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(Canadian Agency for Drugs and Technologies 
in Health, 2006).
Apart from the methods discussed in Tab. 1, 
other economic methods are sometimes used, 
for example, the cost-benefi t analysis or the 
Headroom Method. The cost-benefi t analysis 
(CBA) values costs and outcomes in monetary 
terms. In this method all direct and indirect 
costs of health care are included as well as 
economic valuations of the outcomes. However, 
only economic distinctions are made between 
the value to society or individuals of having 
particular health outcomes. That is why there 
are ethical issues connected with assigning 
monetary values to health outcomes (Sinkey & 
Odibo, 2016).
The Headroom Method is especially 
important in the early assessment of the medical 
device since it can reveal whether the device 
will be commercially viable in the healthcare 
market. This is usually done by estimating the 
maximum reimbursable price (MRP) for a new 
device idea, and comparing this reimbursement 
opportunity with a developer’s expected costs 
(Chapman, Taylor, & Girling, 2013; Girling et al., 
2015).
Overall, as this study and other research 
studies indicate, CUA and CEA are preferred 
methods in the economic evaluations. As 
Mathes et al. (2013) suggest the comparator 
should be usual care. They recommend 
discounting rates range from 1.5-5% for effects 
Aim of the method
Conditions for 
applying the ana-
lysis
Benefi ts Limitations
CBA Facilitate effi cient 
allocation of social 
resources.
Costs and benefi ts 
are identifi ed and 
judged from the 
perspective of the 
company.
It expresses the 
degree of benefi t of 
the program, while 
quantifying the 
benefi ts of monetary 
indicators. It is 
possible to compare 
procedures with 
different types of 
outcomes.
Quantifi cation 
is expressed in 
monetary units, 
these statements 
are inaccurate, plus 
ethical issues.
CEA Compare the costs 
of varied medical 
procedures in relation 
to improving the 
patient‘s condition.
Costs are measured 
against the measure 
of the effect that 
is not expressed 
in monetary units. 
Natural and physical 
units are indicators of 
program implications.
Comparison of 
costs and outputs, 
quantifi cation of 
outputs.
In most cases, it only 
takes into account the 
direct costs, suitable 
for comparison within 
a group.
CUA Assess treatment 
practices that 
only extend the 
prolongation of human 
life to the cost of side 
effects.
It compares the 
cost of one variable. 
Consequences are 
measured in natural 
units.
It accumulates two 
aspects: 1) the length 
of life that is obtained 
through the treatment; 
2) improving the 
quality of life.
The outputs are 
measured by the 
QALY method.
CMA Find a treatment 
procedure whose 
costs are the lowest. 
For identical results 
achieved by reciprocal 
treatment.
It is the simplest of 
the one-criterion cost-
output methods.
Only to compare costs 
and not the outputs. 
Procedures must 
be of comparable 
effectiveness - the 
same outcomes.
Tab. 2: Comparison of methods – Part 1
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and 3-5% for costs although it is desirable to 
use the same rate for costs and effects. In 
addition, the recently developed Headroom 
Method is recommended to be used in the early 
assessment of the medical device development 
since it uses broader estimates of potential by 
determining the maximum reimbursable price 
of the new device. In fact, it is tailored to the 
early assessment needs of medical device 
(Mays & Pope, 2000), which is essential in the 
manufacturers’ decision-making process and 
other potential stakeholders.
Fig. 1 below illustrates a possible 
hierarchical implementation model of the 
economic methods used in the economic 
evaluations of the medical device development.
ICER Show how much more 
funds are needed to 
achieve additional 
therapeutic benefi t.
It is the ratio of cost 
differences and 
effi ciency.
Use for CEA. None.
QALY Determine which 
treatment will bring 
one year of life to 
the highest possible 
quality at the lowest 
possible price.
It assesses:
1) physical status and 
functions,
2) mental state and 
mental functions,
3) social ties,
4) economic status 
and occupation.
Simplicity, clarity 
for many actors: we 
get a single number 
that can be easily 
interpreted.
Various tools for 
measuring quality 
of life, which 
often provide 
confl icting results. 
Methodological 
problems of individual 
questionnaires 
and ways of their 
evaluation.
Source: own
Tab. 2: Comparison of methods – Part 2
Fig. 1: An overview of the recommended economic methods for the economic evaluations of the medical device development
Source: own
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Conclusions
As the fi ndings of this study show, there are 
several methods of economic evaluation whose 
selection depends on the research question, 
the condition of interest, and the availability of 
data on outcomes.
In comparison with the obtained results, the 
CEA, CMA, CUA, ICER and QALY methods 
are used in the Czech Republic for cost 
effectiveness evaluation.
A cost-effective procedure is then 
a procedure which, at comparable costs, brings 
about the same or higher therapeutic effect of 
extending life, improving the quality of life, or 
improving the essential measurable criterion of 
the disease in question. Or a tactical procedure 
which, with at least a comparable therapeutic 
effect, means lower overall costs for the health 
insurance system (Section 15 (8) of the Public 
Health Insurance Act).
As in other areas of health care (Maresova, 
Klimova, & Kuca, 2015; Maresova et al., 
2015a,b; Maresova et al., 2016) there is an 
urgent need to conduct the early assessment 
of the medical device development in order 
to avoid negatively high costs and prevent 
a failure rate at each stage of the development 
process.
This study was supported by the research 
project The Czech Science Foundation 
(GACR) 2017 No. 15330/16/AGR Investment 
evaluation of medical device development, run 
at the Faculty of Informatics and Management, 
University of Hradec Kralove, Czech Republic.
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Abstract
ECONOMIC METHODS USED IN HEALTH TECHNOLOGY ASSESSMENT
Blanka Klímová, Petra Marešová
Early decision-making process about the development of a new product is essential for any 
company in order to gain relevant fi nancial returns and thus prosper. Therefore, managers need to 
have at their disposal appropriate assessment tools which assist them in their decisions about the 
development of the new product and guarantee that their product will generate a desirable profi t. 
The purpose of this review focuses on the exploration of the methodology, commonly used in the 
economic evaluation as part of health technology assessment for medical devices. On the basis of 
the selected original studies, the authors summarize the main methods used in the decision-making 
processes about the development of new medical devices and discuss their benefi ts and limitations. 
The methods employed in this study include a method of literature search in the databases Web 
of Science, MEDLINE, and Embase, and a method of comparison and evaluation of the results. 
The fi ndings of this study indicate that the most preferred methods used in the economic evaluations 
of medical device development are cost-utility analysis and cost-effectiveness analysis. In addition, 
the Headroom Method is recommended to be used in the early assessment of the medical device 
development since it uses broader estimates of potential by determining the maximum reimbursable 
price of the new device. Selection of each method then depends on the research question, the 
condition of interest, and the availability of data on outcomes. There is an urgent need to conduct 
the early assessment of the medical device development in order to avoid negatively high costs and 
prevent a failure rate at each stage of the development process.
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